The Parkinson's-Reversing Breakthrough

Parkinson Disease Treatment Options

Get Instant Access

1. Last JM. A Dictionary of Epidemiology. 3rd ed. New York: Oxford University Press, 1995.

2. Drachman DA, Long RR, Swearer JM. Neurological evaluation of the elderly patient. In: Albert ML, Knoefel JE, eds. Clinical Neurology of Aging. 2nd ed. New York: Oxford University Press, 1994:159-180.

3. Rajput AH. Clinical features of tremor in extrapyramidal syndromes. In: Findley LJ, Koller WC, eds. Handbook of Tremor Disorders. New York: Marcel Dekker, Inc., 1994: 275-291.

4. Rajput A, Robinson C, Rajput AH. Longitudinal study of essential tremor: 21 autopsy cases. Neurology 2004; 62:932-936.

5. de Rijk MC, Rocca WA, Anderson DW, Melcon MO, Breteler MMB, Maraganore DM. A population perspective on diagnostic criteria for Parkinson's disease. Neurology 1997; 48:1277-1281.

6. Rajput AH, Rozdilsky B, Ang L, Rajput A. Significance of Parkinsonian manifestations in essential tremor. Can J Neurol Sci 1993; 20:114-117.

7. Duvoisin R, Golbe LI. Toward a definition of Parkinson's disease. Neurology 1989; 39:746.

8. Rajput AH, Rozdilsky B, Rajput AH. Accuracy of clinical diagnosis in Parkinsonism—a prospective study. Can J Neurol Sci 1991; 18:275-278.

9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: Aclinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184.

10. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features—report of 16 autopsied cases. Mov Disord 2002; 17:1255-1264.

11. Gelb D, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56:33-39.

12. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990; 13(6):553-558.

13. Parkinson J. Abicentenary volume of papers dealing with Parkinson's disease. In: Critch-ley M, McMenemey WH, Walshe FMR, Greenfield JG, eds. London: MacMillan, 1955.

14. Krusz JC, Koller WC, Ziegler DK. Historical review: abnormal movements associated with epidemic encephalitis lethargica. Mov Disord 1987; 3(3):137-141.

15. Kurland LT. Epidemiology: incidence, geographic distribution and genetic considerations. In: Fields WS, ed. Pathogenesis and Treatment of Parkinsonism. Springfield, Illinois: Thomas, 1958:5-43.

16. Nobrega FT, Glattre E, Kurland LT, Okazaki H. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. In: Barbeau A, Brunette JR, eds. Progress in Neurogenetics. Amsterdam: Excerpta Medica, 1967:474-485.

17. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of Parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16:278-282.

18. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52:1214-1220.

19. Baldereschi M, De Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study. Two-fold higher incidence in men. Neurology 2000; 55:1358-1363.

20. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol 1960; 2:511-527.

21. Adams RD, van Bogaert L, Van der Eecken H. Striato-nigral degeneration. J Neuropathol Exp Neurol 1964; 23:584-608.

22. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10:333-359.

23. Jellinger K. The pathology of parkinsonism. In: Marsden CD, Fahn S, eds. Movement Disorders 2. London: Butterworths and Co., 1987:124-165.

24. Jellinger K. Pathology of Parkinsonism. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. New York: Raven Press, 1986:32-66.

25. Rosati G, Graniere E, Pinna L, De Bastiani P, Pirisi A, Devoto MC. The risk of Parkinson's disease in Mediterranean people. Neurology 1980; 32:250-255.

26. Twelves D, Perkins KSM, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003; 18:19-31.

27. Chen RC, Chang SF, Chen TH, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001; 57(9):1679-1986.

28. Ayd FJ. A survey of drug-induced extrapyramidal reaction. JAMA 1961; 175:1054-1060.

29. Rocca WA, Bower JH, McDonnell SK, Peterson BJ, Maraganore DM. Time trends in the incidence of parkinsonism in Olmsted County, Minnesota. Neurology 2001; 57:462-467.

30. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51:745-752.

31. Ross GW, White LR, Petrovitch H, et al. Lack of association of midlife smoking or coffee consumption with presence of Lewy bodies in the locus ceruleus or substantia nigra at autopsy. Neurology 1999; 52(supp 2):A539-A540.

32. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 2002; 55:25-31.

33. Mosewich RK, Rajput AH, Shuaib A, Rozdilsky B, Ang L. Pulmonary embolism: an under-recognized yet frequent cause of death in Parkinsonism. Mov Disord 1994; 9(3):350-352.

34. Beyer MK, Herlofson K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson's disease. Acta Neurol Scand 2001; 103(1):7-11.

35. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442.

36. Kurtzke JF, Flaten TP, Murphy FM. Death rates from Parkinson's disease in Norway reflect increased survival. Neurology 1991; 41:1665-1667.

37. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993; 43:1918-1926.

38. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986; 19:365-372.

39. Diamond SG, Markham CH. Mortality of Parkinson patients treated with Sinemet. Adv Neurol 1979; 24:489-497.

40. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001; 8:95-100.

41. Roos RAC, Jongen JCF, Van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996; 11(3):236-242.

42. Diamond SG, Markham CH. Present mortality in Parkinson's disease: the ratio of expected to observed deaths with a method to calculate expected deaths. J Neural Transm 1976; 38:259-269.

43. Rajput AH, Pahwa R, Pahwa P, Rajput A. Prognostic significance of the onset mode in Parkinsonism. Neurology 1993; 43:829-830.

44. Rajput A, Rajput AH. Progressive supranuclear palsy. Clinical features, pathophysiology and management. Drugs Aging 2002; 18(12):913-925.

45. Rajput AH, Uitti RJ, Rajput A, Offord KP. Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat Disord 1997; 3(3):159-165.

46. Schrag A, Ben-Schlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psych 2002; 73:529-535.

47. Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Dis-ord 2004; 19(3):318-323.

48. Menniti-Ippolito F, Spila-Alegiani S, Vanacore N, et al. Estimate of parkinsonism prevalence through drug prescription histories in the province of Rome, Italy. Acta Neurol Scand 1995; 92(1):49-54.

49. Strickland D, Bertoni JM, Pfeiffer RF. Descriptive epidemiology of Parkinson's disease through proxy measures. Can J Neurol Sci 1996; 23:279-284.

50. Marttila RJ. Epidemiology. In: Koller WC, ed. Handbook of Parkinson's Disease. 2nd ed.—Revised and Expanded ed. New York: Marcel Dekker, Inc., 1992:35-57.

51. Chan DKY, Dunne M, Wong A, Hu E, Hung WT, Beran RG. Pilot Study of prevalence of Parkinson's Disease in Australia. Neuroepidemiology 2001; 20:112-117.

52. Li SC, Schoenberg BS, Wang CC, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985; 42:655-657.

53. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsonism: A door-to-door survey in three Sicilian municipalities. Neurology 1992; 42:1901-1907.

54. Bharucha NE, Bharucha EP, Bharucha AE, et al. Prevalence of Parkinson's disease in the Parsi Community of Bombay, India. Arch Neurol 1988; 45:1321-1323.

55. de Rijk MC, Breteler MMB, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: The Rotterdam study. Neurology 1995; 45:2143—2146.

56. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the bira-cial population of Copiah County, Mississippi. Neurology 1985; 35(6):841-845.

57. Moghal S, Rajput AH, D'Arcy C, Rajput R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994; 13:175-178.

58. Moghal S, Rajput AH, Meleth R, D'Arcy C, Rajput R. Prevalence of movement disorders in institutionalized elderly. Neuroepidemiology 1995; 14:297-300.

59. Vanacore N, Bonifati V, Bellatreccia A, Edito F, Meco G. Mortality rates for Parkinson's disease and Parkinsonism in Italy (l969-l987). Neuroepidemiology 1992; 11:65-73.

60. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990; 40:763-766.

61. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004; 75:637-739.

62. Spencer PS, Palmer VS, Ludolph AC. On the decline and etiology of high-incidence motor system disease in West Papua (Southwest New Guinea). Mov Disord 2005; 20(suppl 12):S199-S126.

63. Lerner MR, Goldman RS. Skin colour, MPTP, and Parkinson's disease. Lancet 1987; 2:212.

64. McInerney-Leo A, Gwinn-Hardy K, Nussbaum RL. Prevalence of Parkinson's disease in populations of African ancestry: a review. J Natl Med Assoc 2004; 96(7):974-979.

65. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in Northern Manhattan, 1988-1993. Am J Epidemiol 1995; 142:820-827.

66. Schoenberg BS, Osuntokun BO, Adejua AOG, et al. Comparison of the prevalence of Parkinson's disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology 1988; 38:645-646.

67. Rajput AH, Gibb WRG, Zhong XH, et al. Dopa-responsive dystonia: pathological and biochemical observations in a case. Ann Neurol 1994; 35:396-402.

68. Tan LC, Venketasubramanian N, Hong CY, et al. Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 2004; 62(11):1999-2004.

69. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157:1015-1022.

70. Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 1983; 40:151-154.

71. Svenson LW. Regional disparities in the annual prevalence rates of Parkinson's disease in Canada. Neuroepidemiology 1991; 10:205-210.

72. Lux WE, Kurtzke JF. Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology 1987; 37:467-471.

73. Lilienfeld DE, Sekkor D, Simpson S, et al. Parkinsonism death rates by race, sex and geography: a 1980's update. Neuroepidemiology 1990; 9:243-247.

74. Rajput AH, Uitti RJ, Stern W, Laverty W. Early onset Parkinson's disease in Saskatchewan. Can J Neurol Sci 1986; 13:312-316.

75. Hertzman C, Wiens M, Bowering D, Snow B, Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Amer J Industrial Med 1990; 17: 349-355.

76. Koller W, Vetere-Overfield B, Gray C, et al. Environmental risk factors in Parkinson's disease. Neurology 1990; 40:1218-1221.

77. Tanner CM, Chen B, Wang W, et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci 1987; 14:419-423.

78. Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993; 43:1693-1697.

79. Seidler A, Hellenbrand W, Robra B-P, Vieregge P. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996; 46:1275-1284.

80. Tanner CM, Chen B, Wang W, Peng M. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989; 39(5):660-664.

81. Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992; 42:13281335.

Was this article helpful?

0 0

Post a comment